TrialThoracic cancer2019

Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.

Shinnosuke Takemoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.